Takeda's 10-year study finds no link between pioglitazone and bladder cancer
Japan’s largest drugmaker Takeda (TYO: 4502) has completed the post-marketing commitment and data submissions to regulators including the US Food and Drug Administration and the European Medicines Agency from a 10-year epidemiology study for pioglitazone-containing medicines. Pioglitazone is approved for the treatment of type 2 diabetes mellitus in more than 100 countries globally.
The study was conducted by the University of Pennsylvania and Division of Research at Kaiser Permanente Northern California and was designed to investigate whether patients exposed to pioglitazone have an increased risk of bladder cancer. It found no statistically significant link between the two.
No association was found between the risk of bladder cancer, and the duration of using the drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze